Nura Bio has secured an additional $68m in a Series A financing round to advance the development of its neuroprotective therapies. The latest funding brings the total funds raised by the company to more than $140m with $73m in an initial Series A round in 2020. The gold standard of business intelligence.
The Column Group led the investment round, with continued support from Samsara Bio Capital and Euclidean Capital, and new backing from Sanofi Ventures. Nura Bio’s recent funding milestone coincides with the successful completion of Phase I studies for its lead clinical candidate, NB-4746, in healthy subjects. A brain-penetrant SARM1 inhibitor, NB-4746 has demonstrated potential in preventing axon degeneration and offering neuroprotection in preclinical models of nerve injury and disease.
The Phase I trial data indicated that NB-4746 was well-tolerated in both single ascending and multiple ascending dose arms, achieving targeted plasma exposure levels believed to be necessary for efficacy without serious treatment-emergent adverse events. Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research.
Gain competitive edge. Your download email will arrive shortly We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form Cerebrospinal fluid levels of NB-4746 confirmed bra.